Immune targeting strategy using anti-IL-7R antibody-drug conjugate (A7R-ADC)

被引：0

作者：

Yang, Shiqi ^{[1
]}

Manabe, Shino ^{[2
]}

Yasunaga, Masahiro

机构：

[1] Natl Canc Ctr, EOR&CT Ctr, Div Dev Therap, Tokyo, Japan

[2] Hoshi Univ, Dept Pharm, Lab Funct Mol Chem, Tokyo, Japan

来源：

CANCER SCIENCE | 2021年 / 112卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PJ12-5-3

引用

页码：744 / 744

页数：1

共 50 条

[41] Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma
Capone, Emily
Lamolinara, Alessia
Pastorino, Fabio
Gentile, Roberta
Ponziani, Sara
Di Vittorio, Giulia
D'Agostino, Daniela
Bibbo, Sandra
Rossi, Cosmo
Piccolo, Enza
Iacobelli, Valentina
Lattanzio, Rossano
Panella, Valeria
Sallese, Michele
De Laurenzi, Vincenzo
Giansanti, Francesco
Sala, Arturo
Iezzi, Manuela
Ponzoni, Mirco
Ippoliti, Rodolfo
Iacobelli, Stefano
Sala, Gianluca
CANCERS, 2020, 12 (10) : 1 - 18
[42] Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting
Schoenfeld, Katrin
Harwardt, Julia
Habermann, Jan
Elter, Adrian
Kolmar, Harald
FRONTIERS IN IMMUNOLOGY, 2023, 14
[43] Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC).
Kurmasheva, Raushan
Mosse, Yael P.
Del Pozo, Vanessa
Earley, Eric J.
Erickson, Stephen W.
Groff, David
Kolb, E. Anders
Krytska, Kateryna
Smith, Malcolm A.
Tsang, Matthew
Teicher, Beverly A.
Gorlick, Richard Greg
Maris, John M.
Houghton, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] Effective targeting of tumor vasculature with an antibody against tumor endothelial marker 7-R (TEM7R)
Liu, M.
Zhang, J.
Shaller, C.
Simmons, H.
Bingham, C.
Robinson, M. K.
Adams, G.
Weiner, L. M.
Borghaei, H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[45] Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors
Xu, Jian
Zong, Qing
Wang, Wei
Liu, Qigang
Stann, Sasha
Cai, Jiaqiang
CANCER RESEARCH, 2023, 83 (07)
[46] A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors
Tolcher, A. W.
Calvo, E.
Maitland, M. L.
Gibson, B.
Xuan, D.
Joh, T.
Jackson-Fischer, A.
Damelin, M.
Barton, J.
Xin, X.
Sachdev, J. C.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S724 - S724
[47] IL-7/IL-7R alpha-Fc immune modulation in lung cancer
Andersson, Asa
Zhu, Li
Elashoff, David
Strieter, Robert
Dubinett, Steven
Sharma, Sherven
CANCER RESEARCH, 2009, 69
[48] A clinical candidate anti-mesothelin-MMAE antibody-drug conjugate (ADC) for therapy of mesothelin-expressing cancers
Scales, Suzie J.
Gupta, Nidhi
Pacheco, Glenn
Firestein, Ron
French, Dorothy M.
Chuh, Josefa
Zhang, Yin
Berry, Leanne
Bostrom, Jenny
Luis, Elizabeth
O'Donohue, Aimee Fourie
Kozak, Katherine R.
Ross, Sarajane
Dennis, Mark S.
Tibbitts, Jay
Spencer, Susan D.
CANCER RESEARCH, 2014, 74 (19)
[49] A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)
Sachdev, J. C.
Maitland, M.
Sharma, M.
Moreno, V.
Boni, V.
Kummar, S.
Gibson, B.
Xuan, D.
Joh, T.
Powell, E.
Jackson-Fisher, A.
Damelin, M.
Xin, X.
Tolcher, A.
Calvo, E.
ANNALS OF ONCOLOGY, 2016, 27
[50] Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.
Xuan, Dawei
Xin, Xiaohua
Gibson, Brenda
Joh, Tenshang
Yin, Hequn
Garzone, Pamela D.
Sachdev, Jasgit C.
Maitland, Michael L.
Sharma, Manish
Moreno, Victor
Calvo, Emiliano
Kummar, Shivaani
Stringer-Reasor, Erica Michelle
Lakhani, Nehal J.
Tolcher, Anthony W.
Beaupre, Darrin M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →